Category: New York Times
-
GenderMenace.net Media Rankings for August 2023
Here at GenderMenace.net, we review a lot of media stories that address gender issues each month. For each story, we provide a rating of “Transsupportive”, “Transneutral”, or “Transphobic”. These labels make it possible to perform an article count for each media source that gives a sense of how to rank them from most transsupportive to…
-
California Attorney General Seeks to Block Transgender Notification Policy
Rating: Transneutral, The New York Times, August 28, 2023 (PDF archive) (HTML archive) (Take Action) Action Recommendations Content Summary California Attorney General Seeks to Block Transgender Notification Policy The News California’s attorney general, Rob Bonta, filed a lawsuit against a Southern California school district on Monday, asking a judge to halt a new requirement that…
-
This Is What Transgender Eradication Looks Like
Rating: Transsupportive, Erin in the Morning, August 23, 2023 (PDF archive) (HTML archive) (Take Action) Action Recommendations Content Summary This Is What Transgender Eradication Looks Like On Monday morning, we learned of a tragic incident: a woman was fatally attacked outside her store by an individual who had torn down the pride flag displayed…
-
GenderMenace.net Media Rankings for June 2023
Here at GenderMenace.net, we review a lot of media stories that address gender issues each month. For each story, we provide a rating of “Transsupportive”, “Transneutral”, or “Transphobic”. These labels make it possible to perform an article count for each media source that gives a sense of how to rank them from most transsupportive to…
-
Britain Limits Use of Puberty-Blocking Drugs to Research Only
Britain’s National Health Service announced on Friday that it would limit the use of puberty-suppressing drugs to children enrolled in clinical trials. The change comes as the agency’s pediatric gender services have struggled to keep up with soaring demand. Rating: Transneutral, New York Times, June 9, 2023 (PDF archive)